The user facility reported to terumo cardiovascular that during cardiopulmonary bypass, the one way valve on the oxy sampling port is blocked, and has a slow flow.No known impact or consequence to patient.The product was not changed out.The procedure was completed successfully.
|
This follow-up report is submitted to fda in accord with applicable regulations and as indicated by terumo cardiovascular systems in the initial report submitted to the fda.Upon further investigation of the reported event, the following information is new and/or changed: (identification of evaluation codes 10, 11, 3331, 180, 4315) method code #1: 10 testing of actual/suspected device.Method code #2: 11 testing of device from same lot/batch retained by manufacturer.Method code #3: 3331 analysis of production records.Results code: 180 mechanical problem identified.Conclusions code: 4315 cause not established.The returned sample was inspected upon receipt with no visual anomalies on the device.The affected manifold was setup in a water circuit and compared to a representative retention sample manifold with flow compared.It was observed water flowed through the retention sample and the affected sample.The one way valves for the complaint and retention samples were disassembled to check for presence of foreign matter, and no foreign matter was present in either valve.All capiox manifolds are 100% leak tested during production.The evaluation of the returned sample confirmed that there was flow through the sample; however, a definitive root cause could not be determined.All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|